Literature DB >> 16735066

Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules.

C Meier1, J Balzarini.   

Abstract

Pronucleotides represent a promising tool to improve the biological activity of nucleoside analogs in antiviral and cancer chemotherapy. The cycloSal-approach is one of several conceptually different pronucleotide systems. This approach can be applied to various nucleoside analogs. A salicyl alcohol as a cyclic bifunctional masking unit is used, and shown to afford a chemically driven release of the particular nucleotide from the lipophilic phosphate triester precursor molecule. A conceptual extension of the cycloSal-approach results in the design of "lock-in"-cycloSal-derivatives. The cycloSal-approach is not restricted to the delivery of bioactive nucleotides but also useful for the intracellular delivery of hexose-1-phosphates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735066     DOI: 10.1016/j.antiviral.2006.04.011

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  19 in total

1.  Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.

Authors:  Carlos M Galmarini; Galya Warren; Madapathage T Senanayake; Serguei V Vinogradov
Journal:  Int J Pharm       Date:  2010-05-24       Impact factor: 5.875

Review 2.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 3.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

4.  Novel anticancer polymeric conjugates of activated nucleoside analogues.

Authors:  Thulani H Senanayake; Galya Warren; Serguei V Vinogradov
Journal:  Bioconjug Chem       Date:  2011-09-09       Impact factor: 4.774

5.  Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir.

Authors:  Larryn W Peterson; Jae-Seung Kim; Paul Kijek; Stefanie Mitchell; John Hilfinger; Julie Breitenbach; Kathy Borysko; John C Drach; Boris A Kashemirov; Charles E McKenna
Journal:  Bioorg Med Chem Lett       Date:  2011-05-03       Impact factor: 2.823

6.  Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy.

Authors:  Yuan Zhang; William Y Kim; Leaf Huang
Journal:  Biomaterials       Date:  2013-02-04       Impact factor: 12.479

Review 7.  Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues.

Authors:  Larryn W Peterson; Charles E McKenna
Journal:  Expert Opin Drug Deliv       Date:  2009-04       Impact factor: 6.648

8.  Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.

Authors:  Carlos M Galmarini; Galya Warren; Ekta Kohli; Arin Zeman; Anton Mitin; Serguei V Vinogradov
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

9.  Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity.

Authors:  Ulrika Eriksson; Larryn W Peterson; Boris A Kashemirov; John M Hilfinger; John C Drach; Katherine Z Borysko; Julie M Breitenbach; Jae Seung Kim; Stefanie Mitchell; Paul Kijek; Charles E McKenna
Journal:  Mol Pharm       Date:  2008-05-16       Impact factor: 4.939

10.  The nucleoside analogue D-carba T blocks HIV-1 reverse transcription.

Authors:  Paul L Boyer; B Christie Vu; Zandrea Ambrose; John G Julias; Svenja Warnecke; Chenzhong Liao; Chris Meier; Victor E Marquez; Stephen H Hughes
Journal:  J Med Chem       Date:  2009-09-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.